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Nevirapine	 is	 an	 inducer	 of	 CYP3A,	 and	 has	 not	 been	 shown	 to	 reduce	 bedaquiline	
concentrations	 significantly	 (van	 Heeswijk	 et	 al.	 2011).	 This	 may	 however	 be	 an	
underestimation	 of	 the	 potential	 drug-interaction,	 which	 may	 result	 in	 sub-therapeutic	













We	 propose	 to	 study	 the	 pharmacokinetics	 of	 bedaquiline	 when	 administered	 with	
nevirapine	 or	 lopinavir/ritonavir	 in	 patients	 with	 tuberculosis.	 Our	 study	 design	 will	 be	































































































































































Bedaquiline	 is	 well	 absorbed	 after	 oral	 administration	 with	 food,	 and	 reaches	 Cmax	 at	 a	
median	 of	 4	 to	 5	 hours.(Andries	 et	 al.	 2005)	 Bedaquiline	 is	 largely	 metabolized	 by	
cytochrome	P450	(CYP)	3A	to	a	less	active	N-monodesmethyl	metabolite	(M2).	It	undergoes	
triphasic	 elimination,	 and	 although	 the	 average	 half-life	 over	 a	 dosing	 interval	 is	







Table 2. Bedaquiline dosing schedule 
 Week 1 and 2 
 
Week 3 to week 24 



























Week	2	 3270	±1144	 956	±557	 1770	±701	
Week	8	 1659	±722	 620	±466	 902	±535	
		
The	majority	 of	 patients	 achieved	 average	 steady-state	 plasma	 concentrations	 above	 the	
















































Efavirenz	 is	 a	 non-nucleotide	 reverse	 transcriptase	 inhibitor	 (NNRTI)	 and	 an	 inducer	 of	
CYP3A.	 In	a	phase	1	drug	 interaction	study	 in	33	healthy	subjects,	single-dose	bedaquiline	
AUC	 was	 reduced	 by	 a	 median	 of	 20%	 when	 administered	 with	 steady-state	 efavirenz	
(Dooley	 et	 al.	 2012).	 The	 authors	 considered	 this	 unlikely	 to	 be	 clinically	 significant,	 but	
subsequent	 population	 pharmacokinetic	modeling	 estimated	 that	 the	 reduction	 in	 steady	
state	bedaquiline	concentrations	could	be	as	high	as	50%	(Svensson	et	al.	2013).	In	addition,	
the	Cmax	of	 the	 less-active,	 toxic	bedaquiline	metabolite	M2	was	 increased	by	89%	when	
co-administered	 with	 efavirenz.	 The	 AUC	 of	 M2	 did	 not	 differ	 significantly.	 Efavirenz	 is	
therefore	not	recommended	for	concomitant	use	with	bedaquiline	in	the	BCAP.		
	
Nevirapine	 is	 also	 an	 inducer	 of	 CYP3A.	 In	 a	 phase	 1	 drug-interaction	 study	 in	 16	 HIV-1	
infected	 participants,	 single-dose	 bedaquiline	 AUC	 was	 not	 affected	 by	 steady-state	
nevirapine,	 but	 bedaquiline	 Cmax	 was	 reduced	 by	 20%	 (van	 Heeswijk,	 et	 al.	 DATE).	 The	
ratios	of	the	Least	Squares	means	of	bedaquiline	Cmax	was	0.80	(90%	CI	0.62-1.04)	and	AUC	




that	 co-administered	 nevirapine	 will	 not	 significantly	 decrease	 the	 bedaquiline	
concentration	 and	 have	 a	 consequent	 negative	 effect	 on	 bedaquiline	 efficacy.	 Nevirapine	
may	also	increase	the	AUC	or	Cmax	of	the	metabolite	M2,	and	result	in	toxicity.	
	
Ritonavir	 is	 an	 inhibitor	 of	 CYP3A,	 and	 is	 used	 in	 combination	 with	 lopinavir	 as	 the	 first	































We	will	 study	 the	 pharmacokinetics	 of	 bedaquiline	 when	 administered	 in	 HIV-uninfected	
and	HIV-infected	patients	 (with	or	without	ARVs)	treated	for	pre-XDR	or	XDR-TB	nested	 in	
the	national	BCAP.	We	will	use	intensive	PK	sampling	to	better	define	the	pharmacokinetics	
of	bedaquiline	 in	patients	by	HIV	 status,	 and	 to	 study	 the	potential	ARV-bedaquiline	drug	
interactions.	
We	will	collect	data	on	bedaquiline	and	its	metabolite	M2	data	using	intensive	PK	sampling	
in	 the	 maintenance	 phase	 of	 treatment	 (after	 week	 2).	 To	 assess	 for	 potential	 drug-

















































































1	hr	 3	hrs	 4	hrs	 5	hrs	 6	hrs	 8	hrs	 24	hrs	 48	hrs	
Example	 Time	 08h55	 09h00	 10h00	 12h00	 13h00	 14h00	 15h00	 17h00	 09h00	 09h00	


























































Patients	 receiving	 bedaquiline	 will	 be	 approached	 for	 enrolment	 into	 the	 bedaquiline/PK	
study.		
6.2.	Enrolment	
Eligible	 participants	 will	 be	 enrolled	 after	 obtaining	 written	 informed	 consent.	 We	 will	













• Routine	 baseline	 blood	 results:	 ALT,	 Haemoglobin,	 creatinine,	 and	 creatinine	
clearance,	 viral	 load,	 and	 CD4+	 count.	 If	 not	 done	 by	 the	 physician	 caring	 for	 the	















A	 venous	 blood	 sample	 of	 4ml	 blood	 collected	 in	 a	 K3	 EDTA	 tube	 will	 be	 collected	 for	
bedaquiline	analysis	at	the	time-points	specified	above.		
	












































used	 to	 determine	 bedaquiline	 and	M2	 concentrations	 in	 the	 plasma	 samples	 in	 the	UCT	




internal	 standards	 (TMC07-d6	 and	 M2-d3),	 followed	 by	 high	 performance	 liquid	
chromatography	with	MS/MS	detection	using	an	ABSCIEX	API4000.	20	μL	aliquots	of	plasma	




precursor	 ions	m/z	 555.2,	m/z	 541.1,	m/z	 561.1,	 and	m/z	 545.3	 to	 the	 product	 ions	m/z	
58.1,	m/z	480.1,	m/z	64.3,	and	m/z	480.1	for	bedaquiline	(TMC207),	M2,	TMC07-d6	and	M2-



































consequences	 of	 the	 study	 to	 the	 study	 participants.	 When	 necessary,	 a	 competent	
translator	 familiar	 with	 the	 study	 will	 assist	 in	 the	 informed	 consent	 process.	 A	 witness	
independent	of	the	study	will	countersign	the	consent	documents	of	illiterate	patients.	Each	



































of	 Cape	 Town.	 Approval	 of	 the	 protocol	 and	 any	 amendments	 will	 be	 obtained	 before	
implementation.	The	study	will	be	conducted	in	accordance	with	the	Declaration	of	Helsinki	










































































You	 are	 invited	 to	 take	 part	 in	 the	 research	 study,	 entitled:	 	 Drug-drug	 interactions	 between	
bedaquiline	and	antiretrovirals:	a	population	pharmacokinetic	approach	(BDQ.ART	study).	





























effective	 in	 treating	 tuberculosis.	However,	we	do	not	 know	whether	 it	 is	 safe	or	 effective	 to	use	
bedaquiline	at	the	same	time	as	certain	antiretroviral	treatments.	One	of	the	concerns	is	that	certain	
antiretrovirals	may	increase	the	blood	levels	of	bedaquiline,	and	thus	increase	the	risk	of	developing	
side-effects.	 Conversely,	 certain	 antiretrovirals	may	 decrease	 the	 blood	 levels	 of	 bedaquiline,	 and	
thus	may	make	 bedaquiline	 less	 effective	 in	 treating	 the	 tuberculosis.	 If	 you	 are	HIV	 positive,	we	
want	 to	 study	 whether	 the	 antiretrovirals	 you	 are	 using,	 will	 increase	 or	 decrease	 the	 levels	 of	























Study	 treatments:	 This	 study	 will	 not	 affect	 the	 treatments	 you	 are	 receiving.	 During	 the	 study	
period	you	will	 continue	 to	 take	your	 regular	 treatment	 for	 tuberculosis,	and	antiretrovirals	 if	 you	
are	HIV	positive.		
	























We	 will	 not	 change	 your	 tuberculosis	 or	 antiretroviral	 treatment.	 	 We	 will	 be	 taking	 blood	 to	




















You	 are	 unlikely	 to	 benefit	 personally	 from	 taking	 part	 in	 this	 study.	 The	 results	 of	 the	 study	will	
benefit	future	patients	who	need	treatment	for	tuberculosis	and	HIV	at	the	same	time.	However,	if	




Yes,	 as	 far	 as	 is	 possible.	 Your	 medical	 records	 will	 be	 seen	 by	 some	 of	 the	 study	 staff,	 and	 by	
authorized	persons	who	check	to	see	that	the	research	 is	being	carried	out	correctly.	Your	records	
may	 also	 be	 seen	 by	 representatives	 of	 the	 South	 African	 regulatory	 authority	 (MCC)	 or	 the	 UCT	





















If	 you	 want	 any	 information	 regarding	 your	 rights	 as	 a	 research	 participant,	 or	 have	 complaints	













..….….……..…..………..….….……………(STUDY	 DOCTOR	 /	 DESIGNATED	 STUDY	 TEAM	 MEMBER)	 has	 provided	 me	
with	 a	 copy	 of	 this	 informed	 consent	 form	 regarding	 the	 study,	 Drug-drug	 interactions	 between	




































Patient	name	 	 Hospital/Clinic	number	 	
Date	of	birth	 	 Study	site	name	 	





























Date	started	 Regimen	 Date	Stopped/Changed	 Reason	for	stop/change	
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Date	 K+	 Creatinine	GFR	 ALT	 Hb	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	












































Patient	name	 	 Study	ID	number	 	
Hospital	number	 	 Study	site	name	 	

















01	 Pre-dose	 	 	 	 	 	
											Time	of	observed	dose:						HH	:	MM																									Dose	in	mg:			______________	
02	 +1hr	 	 	 	 	 	
03	 +3hrs	 	 	 	 	 	
04	 +4hrs	 	 	 	 	 	
05	 +5hrs	 	 	 	 	 	
06	 +6hrs	 	 	 	 	 	
07	 +8hrs	 	 	 	 	 	
Day	2:		DD	/	MM	/	YYYY	
08	 +24hrs	 	 	 	 	 	
Day	3:		DD	/	MM	/	YYYY	
























































































































































































































































































































































































































































































































































































































































































Bedaquiline	 and	 M2	 concentrations	 were	 determined	 using	 a	 LC-MS/MS	 assay	 validated	






the	mobile	phase,	delivered	at	a	 constant	 flow	 rate	of	500	µl/min.	 	An	AB	Sciex	API	4000	
mass	 spectrometer	 was	 operated	 at	 unit	 resolution	 in	 the	 multiple	 reaction	 monitoring	











was	 validated	 over	 the	 concentration	 range	 of	 0.00977	 –	 5	 µg/ml	 for	 bedaquiline	 and	
0.00313	–	0.2	µg/ml	 for	M2.	During	 inter-day	 sample	analysis,	 the	accuracies	 (%Nom)	 for	
bedaquiline	were	97.2%,	96.9%	and	104.1%	at	the	high	(3.75	µg/ml),	medium	(1.75	µg/ml)	
and	low	(0.0293	µg/ml)	QC	levels	respectively	with	precision	less	than	10%	across	all	three	
levels.	 	 The	 accuracies	 for	M2	were	 97.5%,	 101.4%	 and	 99.9%	 at	 the	 high	 (0.150	 µg/ml),	






































































































































Male	sex	(%)	 13	(77%)	 10	(59%)	 9	(64%)	
Age,	years	 25	(22-38)	 37	(21-46)	 32	(26–40)	








P	value*	 Referent	 P=0.502	 P=0.003	
Cmax,	ng/mL	 1970	(1100-2640)	 2000	(1420-2450)	 2235	(1670-2850)	
P	value*	 Referent	 P=0.642	 P=0.234	
Tmax,	hours		 4	(3-5)	 5	(4-6)	 6	(5-8)	
P	value*	 Referent	 P=0.197	 P=0.003	
Half-life,	hours**	 31	(24-37)	 33	(26-44)	 55	(44-93)	
P	value*	 Referent	 P=0.564	 P=0.004	
M2	metabolite	
AUC0-48,	ng.hr.mL-1		 7449	(6064-9060)	 8358	(4943-9537)	 6561	(3846-10626)	
P	value*	 Referent	 P=0.617	 P=0.606	
Cmax,	ng/mL	 169	(140-244)	 185	(128-281)	 172	(103-258)	






Tmax,	hours		 8	(5-8)	 6	(0-8)	 8	(3-24)	
P	value*	 Referent	 P=0.391	 P=0.587	
Half-life,	hours***	 208	(120-447)	 240	(124-477)	 243	(72-1233)	













Nevirapine	 17%	increase	 -17%	to	65%	 0.340	
LPV/r	 62%	increase	 13%	to	132%	 0.010	







Age	(per	year	increase)	 0.9%	increase	 -1%	to	24%	 0.186	
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